Polosan, Mircea
Droux, Fabien
Kibleur, Astrid
Chabardes, Stephan
Bougerol, Thierry http://orcid.org/0000-0002-8357-7424
David, Olivier
Krack, Paul
Voon, Valerie
Funding for this research was provided by:
Agence Nationale de la Recherche (14-CE13-0030-01 Physiobs)
University Hospital of Grenoble
Wellcome Trust (983705/Z/10/Z)
Article History
Received: 28 January 2018
Revised: 23 September 2018
Accepted: 1 January 2019
First Online: 4 February 2019
Conflict of interest
: M.P. has received reimbursement for travelling costs for participation in scientific meetings by Medtronic and honoraria for lecturing or consultation from the Movement Disorder Society, Lundbeck. P.K. has received research support from Orkyn, Novartis, UCB, Medtronic, LVL, Boston Scientific, and St Jude, and honoraria for lecturing or consultation from the Movement Disorder Society, Lundbeck, Boehringer Ingelheim, Novartis, UCB, Medtronic, Orkyn, Abbott, Orion, TEVA, and Boston Scientific. S.C. has received honoraria for consultation from Medtronic, Boston Scientific. V.V. is a Medical Research Council Senior Clinical Fellow (MR/P008747/1). She has acted as an expert witness for the court related to dopamine agonists and deep brain stimulation. The remaining authors declare that they have no conflict of interest.
: The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.